To increase the accuracy of diagnosis, clinical glioma classification has recently gravitated toward the analysis of mutations on the core driver genes, such as those of isocitrate dehydrogenase (IDH), epidermal growth factor receptor (EGFR), phosphatase and tensin homolog (PTEN), tumor protein p53 (TP53), telomerase reverse transcriptase (TERT) promoter, protein tyrosine phosphatase receptor type Z1 (PTPRZ1), as well as O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation [2, 7]. This evidence concerns the gene TERT and glioma.